Wolfe Research initiated coverage on Gilead Sciences with a new price target
$GILD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Wolfe Research initiated coverage of Gilead Sciences with a rating of Outperform and set a new price target of $110.00